Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumor 17Solid Tumor 7Advanced Solid Tumors 5Locally Advanced or Metastatic Solid Tumors 2Solid Tumor, Adult 1Mesothelioma, Malignant 1DMMR Colorectal Cancer 1Advanced Solid Tumours 1Advanced Malignant Solid Tumors 1

Interventions

adavosertib 5durvalumab 3Paclitaxel 3olaparib 2ceralasertib 2Fluorouracil 2Carboplatin 2toripalimab 1sintilimab 1pembrolizumab 1factor IX, factor VII, factor X, prothrombin drug combination 1drug XX Z 1danvatirsen 1capivasertib 1Rifampin 1Pantoprazole 1Omeprazole 1Leucovorin 1Itraconazole 1Irinotecan 1Injections 1Gemcitabine 1Doxorubicin 1Cisplatin 1AZD0156 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumours × toripalimab × Other solid neoplasm × Clear all
NCT06868199 2025-09-12

A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

LaNova Medicines Limited

Phase 1/2 Recruiting
87 enrolled
Other solid neoplasm

Advanced Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡